Abstract
Management of maternal red cell alloimmunization has been revolutionized over the last 60 years. Advances in the prevention, screening, diagnosis, and treatment of alloimmune-induced fetal anemia make this condition an exemplar for contemporary practice in fetal therapy. Since survival is now an expectation, attention has turned to optimization of long-term outcomes following an alloimmunized pregnancy. In this review, the current management of red cell alloimmunization is described. Current research and future directions are discussed with particular emphasis on later life outcomes after alloimmune fetal anemia.
© 2020 John Wiley & Sons, Ltd.
Publication types
-
Historical Article
-
Review
MeSH terms
-
Blood Transfusion, Intrauterine
-
Erythroblastosis, Fetal / diagnosis
-
Erythroblastosis, Fetal / epidemiology
-
Erythroblastosis, Fetal / therapy
-
Female
-
Fetal Diseases / diagnosis
-
Fetal Diseases / epidemiology
-
Fetal Diseases / therapy
-
History, 21st Century
-
Humans
-
Pregnancy
-
Prenatal Care / history
-
Prenatal Care / methods
-
Prenatal Care / trends
-
Prenatal Exposure Delayed Effects / blood
-
Prenatal Exposure Delayed Effects / epidemiology
-
Prenatal Exposure Delayed Effects / therapy
-
Rh Isoimmunization / diagnosis
-
Rh Isoimmunization / epidemiology
-
Rh Isoimmunization / etiology
-
Rh Isoimmunization / therapy*